JNK-IN-8 | Covalent JNK inhibitor

JNK-IN-8 chemical structure Focus Biomolecules

Available Options

Size:PriceQuantity 
5 mg$50.00
25 mg$200.00
Request Quote / Bulk / Custom Size
Product Inquiry
This product is also available in the following library:
Highly-Selective Kinase Inhibitor Library

JNK-IN-8 (1410880-22-6) is a  potent and selective irreversible JNK inhibitor (IC50s=4.67, 18.7 and 0.98 nM for JNK1, 2 and 3 respectively).1  JNK blockade with JNK-IN-8 overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer.2  Improves ARDS-induced cognitive impairment by inhibition of JNK/NF-kB-mediated NLRP3 inflammasome activation.3

References/Citations:

  1. Zhang et al. (2012), Discovery of potent and selective covalent inhibitors of JNK; Chem. Biol. 19 140
  2. Sun et al. (2021), Irreversible JNK blockade overcomes PD-Li-mediated resistance to chemotherapy in colorectal cancer; Oncogene 40 5105
  3. Shi et al. (2023), JNK-IN-8 treatment improves ARDS-induced cognitive impairment by inhibiting JNK/NF-kB-mediated NLRP3 inflammasome; Brain Behav. 13 e2980
1410880-22-6, JNK-IN-8, JNK-IN-8 supplier

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

JNK-IN-8 (1410880-22-6) is a  potent and selective irreversible JNK inhibitor (IC50s=4.67, 18.7 and 0.98 nM for JNK1, 2 and 3 respectively).1  JNK blockade with JNK-IN-8 overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer.2  Improves ARDS-induced cognitive impairment by inhibition of JNK/NF-kB-mediated NLRP3 inflammasome activation.3

References/Citations:

  1. Zhang et al. (2012), Discovery of potent and selective covalent inhibitors of JNK; Chem. Biol. 19 140
  2. Sun et al. (2021), Irreversible JNK blockade overcomes PD-Li-mediated resistance to chemotherapy in colorectal cancer; Oncogene 40 5105
  3. Shi et al. (2023), JNK-IN-8 treatment improves ARDS-induced cognitive impairment by inhibiting JNK/NF-kB-mediated NLRP3 inflammasome; Brain Behav. 13 e2980